Nektar Therapeutics Status
The company (NASDAQ: NKTR) received $1.85 billion of development capital from Bristol-Myers Squibb on August 8, 2018.
Developer of bio-pharmaceutical medicines created to offer new pathways that treat serious and widespread unmet medical needs. The company's bio-pharmaceutical products include investigational drugs which are used for the treatment of cancer, auto-immune disease and chronic pain, enabling patients to recover from chronic illness.
Year Founded
1990
Employees
509
RevenueTTM 3Q2018
$1.2 B
Net IncomeTTM 3Q2018
$745.7 M
General Information
-
Website
-
Business Status
Profitable
-
Ownership Status
Publicly Held
-
Financing Status
Corporate Backed or Acquired
Nektar Therapeutics News and Updates
US close: Stocks end higher as GDP data keep hopes of soft landing ...
London South East | January 26, 2023
Trials In Focus: How COVID-19 Studies Set New Standards For ...
Scrip | January 26, 2023
The State of New Jersey Common Pension Fund D sells 69,586 ...
Best Stocks | January 25, 2023
Five Clinical Trial Misses Of 2022
Scrip | January 24, 2023
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Simply Wall St | January 24, 2023
Refractory Multiple Myeloma Pipeline Appears Robust With 80+ Key ...
Digital Journal | January 23, 2023
Nektar Therapeutics's Feed
Nektar Therapeutics's Verticals
Nektar Therapeutics Primary Industry Sector / Group / Code
Nektar Therapeutics's Trends
Nektar Therapeutics Metrics
Growth Rate
SimilarWeb Unique Visitors
Majestic Referring Domains
Twitter Followers
Headquarters
-
HQ Address Line 1455 Mission Bay Boulevard South
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94158
-
HQ CountryUnited States
Nektar Therapeutics's Keywords
Add a review